跳至主要内容
临床试验/NCT05470920
NCT05470920招募中不适用

Randomized, Controlled Trial of an Electronic Decision Aid for Genetic Testing in Inherited Cancer Syndromes

Massachusetts General Hospital4 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
350
试验地点
4
主要终点
Shared Decision Making Process Scores

研究概览

简要总结

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer

详细描述

The research study procedures include: screening for eligibility and study questionnaires that would be performed in conjunction with either the genetic counselor visit or use of the electronic decision aid. The study questionnaires include:

  • Knowledge Survey
  • Shared Decision Making Process Survey
  • Decisional Conflict Scale

The research study will last up to 2 weeks. It is expected that about 350 people will take part in this research study.

The National Cancer Institute (NCI) is supporting this research study by providing funding for the research

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older
  • Being seen in clinic at Massachusetts General Hospital or Boston Medical Center
  • Diagnosed with malignant epithelial ovarian carcinoma or malignant pancreatic adenocarcinoma.
  • Exclusion Criteria :
  • Unable or unwilling to provide informed consent, undergo randomization, or complete the surveys associated with the study
  • Previous germline genetic testing
  • History of hereditary pancreatitis
  • Members of the following vulnerable populations: adults unable to consent, individuals who are not yet adults

排除标准

  • 未提供

结局指标

主要结局

Shared Decision Making Process Scores

时间窗: 1 week after genetics session

The shared decision making process score is a score on a scale of 1-4 based on responses on a validated 4-item shared-decision making scale. The scale assesses how well the decision aid/oncology provider, or the genetic counselor engaged in shared decision-making as perceived by the subject. Higher scores on this scale indicate more shared decision making.

Average change in knowledge survey score

时间窗: baseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks

Average change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.

Decisional Conflict Scores

时间窗: 1 week after genetics session

The decisional conflict score is a score ranging from 0-100 that is measured from a 10-question validated decisional conflict scale. The scale assesses participant's confidence in their decision with higher scores indicating higher decisional conflict.

次要结局

  • Average time between genetic testing recommendation and sample collection(Initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months)
  • Average Duration of Decision Making Process(Approximately 30 minutes - 1 hour)
  • Ratio of the number of participants who chose each of the three panels offered(At the conclusion of genetics session (day 1))
  • Percentage of participants choosing genetic testing(At the conclusion of genetics session (day 1))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel C Chung

Principal Investigator

Massachusetts General Hospital

研究点 (4)

Loading locations...

相似试验

Genetic Testing Decision Aid | 临床试验